Preclinical biotech developing enzyme-based drugs for skin diseases
| Date | Round | Amount |
|---|---|---|
| Oct 2022 | Seed Copenhagen biotech Henlez raised a EUR1M seed round from Eir Ventures and Karolinska Development to advance its lead skin-disease program. | $1.1M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.